SlideShare a Scribd company logo
BACKGROUND
ASTHMA
Journal of Allergy and Clinical Immunology. 2007;120(5):S94-S138.
LEARNING
OBJECTIVES
Outline the major change in the
2019 Global Initiative for Asthma
(GINA) guidelines
Discuss budesonide-formoterol’s
place in therapy for mild asthma
based on recent literature
Recognize the dose and dosage
form that budesonide-formoterol is
supplied as
MEASUREMENTS
OF ASTHMA
CONTROL
Severity
Intrinsic
intensity of
the disease
process
Control
Degree to
which they
are
minimized
Responsivene
ss
The ease with
which control is
achieved by
therapy
Journal of Allergy and Clinical Immunology. 2007;120(5):S94-S138.
CONSEQUENCES OF UNCONTROLLED
ASTHMA
Airway remodeling
Scarring of the lungs
Permanent decline in respiratory function
Journal of Allergy and Clinical Immunology. 2007;120(5):S94-S138.
Beasley RD et al. NEJM. 2019; 380(21):2020-2030.
NOVEL START TRIAL:
CONTROLLED TRIAL OF BUDESONIDE-
FORMOTEROL AS NEEDED FOR MILD
ASTHMA
PURPOSE
ICS use is low as maintenance therapy for mild asthma
An ICS + LABA takes advantage of a patient’s natural
response to use therapy when symptomatic
Two previous clinical trials have been done showing
efficacy and safety in using budesonide-formoterol as
needed
These two trials had high internal validity, but low external
validity
Novel START trial was designed to overcome limitations
of previous 2 trials
Beasley RD et al. NEJM. 2019; 380(21):2020-2030.
PREVIOUS TRIALS
SYGMA-1
• Conclusion: inhaled
budesonide-formoterol
when used as needed
was superior to
terbutaline, but was
inferior to budesonide
maintenance therapy
SYGMA-2
• Conclusion: inhaled
budesonide-formoterol
was non-inferior to the
budesonide
maintenance therapy
for severe
exacerbation
• Bateman E et al. NEJM. 2018;378(20):1877-1887.
CLINICAL QUESTION
• In patients with mild asthma treated only with as-needed
asthma, does budesonide+formoterol reliever therapy used
as-needed reduce the risk of asthma exacerbations
compared to albuterol as-needed?
TRIAL DESIGN
• Multicenter, open-label, parallel-group, randomized, controlled
trial
• N=668
• Albuterol (n=223)
• Budesonide BID+albuterol PRN (n=225)
• Budesonide+formoterol PRN (n=220)
• Setting: 16 centers in New Zealand, United Kingdom, Italy, and
Australia
• Enrollment: 2016-2017
• Follow-up: 52 weeks
• Analysis: Intention-to-treat
• Primary outcome: Asthma exacerbations per patient per year
POPULATION
Inclusion Criteria
• Aged 18-75 years
• Asthma diagnosis, with one of the following:
• If no severe exacerbations in the prior year, SABA use on ≥2
occasions in the prior 4 weeks and ≤2 occasions per day
(average) in prior 4 weeks
• If a severe exacerbation in the prior year (not requiring
hospitalization), SABA use ≤2 occasions per day in the
previous 4 weeks
• Exclusion Criteria
• Hospitalization for asthma in the previous 12 months, or any
admissions to an ICU for asthma
• Smoking with >20 PYH
• Self-reported onset of respiratory symptoms after the ago of 40
years in current or previous smokers with at least a 10 pack-year
smoking history
• Maintenance therapy with ICS, LABA, leukotriene receptor
antagonist, theophylline, anticholinergic agent or cromone in prior
3 months
• Treatment with oral prednisone in the prior 6 weeks, or a home
supply of prednisone for use in worsening asthma
• COPD, bronchiectasis, ILD, HF, unstable CAD, AF, other
significant cardiac disease
• Pregnancy
• Unwilling to switch asthma treatment
• FEV1 ≤50% predicted at visit 1
INTERVENTIONS
• Randomized 1:1:1 to a group:
• Albuterol PRN - Albuterol dose 100 ug
• Budesonide BID+albuterol PRN - Budesonide dose 200 ug,
albuterol dose 100 ug
• Budesonide+formoterol PRN - Budesonide+formoterol dose 200-6
ug
• Electronic monitors recorded inhaler use
• Withdrawal from trial after a severe exacerbation (worsening
asthma leading to prescription of systemic glucocorticoid
treatment for at ≥3 days or hospitalization/ED visit leading to
systemic glucocorticoid treatment), 3 exacerbations separated
by ≥7 days, or unstable disease requiring change in
medication from what they were assigned
OUTCOMES
• Presented as budesonide+formoterol PRN vs. albuterol PRN vs.
budesonide BID+albuterol PRN
Primary Outcomes
• Annual rate of asthma exacerbationsExacerbations was defined
as worsening asthma that leading to an urgent outpatient, ED, or
inpatient medical care consultation, prescription of systemic
glucocorticoids for any duration, or an episode of high β2-agonist
use (>16 actuations of albuterol or >8 actuations of
budesonide+formoterol in 24 hours).
RESULTS: PRIMARY OUTCOME
0.4
0.175
0.195
0
0.05
0.1
0.15
0.2
0.25
0.3
0.35
0.4
0.45
Albuterol Group Budesonide Maintenance
Group
Budesonide-Formoterol Group
Annualized Exacerbation Rate
*
Beasley RD et al. NEJM. 2019; 380(21):2020-2030.
* P < 0.05
Secondary outcomes
• The risk of exacerbation in the budesonide–formoterol group was
lower than that in the albuterol group, as assessed in a time-to-
first-event analysis and did not differ significantly from that in the
budesonide maintenance group.
• Across all time points, the score on the ACQ-5 was lower in the
budesonide–formoterol group than in the albuterol group, but
was higher in the budesonide–formoterol group than in the
budesonide maintenance group.
STRENGHTS
• Good trial design
• Good monitoring and follow up.
• Criticisms
• Insufficiently powered (225
participants per study arm
required to achieve sufficient
power as per reported calculation)
• Lack of smoking pack-year history
(SPYH) stratification
• Mean age of 35.6 limits external
validity for older patient
populations
WEAKNESSES
CRITICISM
IMPLICATIONS
• If available and not costly a very budesonide-formoterol will be
practice changing in our setting
MOVING FORWARD
FDA approval
for
budesonide-
formoterol
Turbuhaler
Changes in
labeling of
budesonide-
formoterol
Further trials
with variety
of doses and
long-term
effects
Guideline
update
Low dose ICS whenever
SABA taken, or daily LTRA,
or add HDM SLIT
Medium dose ICS, or
add LTRA, or add
HDM SLIT
Add LAMA or LTRA or
HDM SLIT, or switch to
high dose ICS
Add azithromycin (adults) or
LTRA. As last resort consider
adding low dose OCS but
consider side-effects
RELIEVER: As-needed short-acting beta2-agonist
STEP 1
Take ICS whenever
SABA taken
STEP 2
Low dose
maintenance ICS
STEP 3
Low dose
maintenance
ICS-LABA
STEP 4
Medium/high
dose maintenance
ICS-LABA
STEP 5
Add-on LAMA
Refer for assessment
of phenotype. Consider
high dose maintenance
ICS-LABA, ± anti-IgE,
anti-IL5/5R, anti-IL4R,
anti-TSLP
RELIEVER: As-needed low-dose ICS-formoterol
STEPS 1 – 2
As-needed low dose ICS-formoterol
STEP 3
Low dose
maintenance
ICS-formoterol
STEP 4
Medium dose
maintenance
ICS-formoterol
STEP 5
Add-on LAMA
Refer for assessment
of phenotype. Consider
high dose maintenance
ICS-formoterol,
± anti-IgE, anti-IL5/5R,
anti-IL4R, anti-TSLP
Treatment of modifiable risk factors
and comorbidities
Non-pharmacological strategies
Asthma medications (adjust down/up/between tracks)
Education & skills training
Adults & adolescents
12+ years
Personalized asthma management
Assess, Adjust, Review
for individual patient needs
Symptoms
Exacerbations
Side-effects
Lung function
Patient satisfaction
Confirmation of diagnosis if necessary
Symptom control & modifiable
risk factors (see Box 2-2B)
Comorbidities
Inhaler technique & adherence
Patient preferences and goals
CONTROLLER and
PREFERRED RELIEVER
(Track 1). Using ICS-formoterol
as reliever reduces the risk of
exacerbations compared with
using a SABA reliever
Other controller options for either
track (limited indications, or less
evidence for efficacy or safety)
CONTROLLER and
ALTERNATIVE RELIEVER
(Track 2). Before considering a
regimen with SABA reliever,
check if the patient is likely to be
adherent with daily controller
See GINA
severe
asthma guide
© Global Initiative for Asthma, www.ginasthma.org
GINA 2022, Box 3-5A
AUTHOR’S
CONCLUSIONS
• Among patients with mild
asthma, the risk of asthma
exacerbations was lower with
budesonide-formoterol used as
needed than with albuterol used
as needed
Beasley RD et al. NEJM. 2019; 380(21):2020-
2030.
FURTHER
DISCUSSION
CURRENT BUDESONIDE-
FORMOTEROL FORMULATION
HFA inhaler available in the US
Label: NOT for use during acute bronchospasm
Asthma approved dose: 80 mcg/4.5 mcg or 160 mcg/4.5 mcg
Formoterol onset of action: 15 minutes
Albuterol onset of action: 25 minutes
Budesonide- Formoterol. Lexi-Drugs. Lexicomp
BUDESONIDE 80 MCG &
FORMOTEROL 4.5 MCG
BUDESONIDE 160 MCG &
FORMOTEROL 4.5 MCG
BUDESONIDE-FORMOTEROL
Dose = 2 inhalations twice daily
SUMMARY
Budesonide-formoterol as-needed
lowers exacerbation rates
2022 GINA guidelines have been
updated to include using
budesonide-formoterol as-needed
first line for mild asthma
Budesonide-formoterol is an HFA
inhaler available as 2 strengths
THANK YOU

More Related Content

What's hot

Allergic bronchopulmonary aspergillosis
Allergic bronchopulmonary aspergillosisAllergic bronchopulmonary aspergillosis
Allergic bronchopulmonary aspergillosis
Chulalongkorn Allergy and Clinical Immunology Research Group
 
201911 - Rossi - L'asma grave è sempre “grave”?
201911 - Rossi - L'asma grave è sempre “grave”?201911 - Rossi - L'asma grave è sempre “grave”?
201911 - Rossi - L'asma grave è sempre “grave”?
Asmallergie
 
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
Sarfraz Saleemi
 
difficult to treat asthma.pptx
difficult to treat asthma.pptxdifficult to treat asthma.pptx
difficult to treat asthma.pptx
Emil Mohan
 
Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma
Controlled Trial of Budesonide–Formoterol  as Needed for Mild AsthmaControlled Trial of Budesonide–Formoterol  as Needed for Mild Asthma
Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma
Ching-wen Lu
 
COPD new drugs new devices
COPD new drugs new devicesCOPD new drugs new devices
COPD new drugs new devices
Ashraf ElAdawy
 
Asthma Evolving approaches to treatment decisions
Asthma  Evolving approaches to treatment decisionsAsthma  Evolving approaches to treatment decisions
Asthma Evolving approaches to treatment decisions
Ashraf ElAdawy
 
Severe asthma management
Severe asthma managementSevere asthma management
Severe asthma management
SCGH ED CME
 
GINA 2019 presentation
GINA 2019 presentationGINA 2019 presentation
GINA 2019 presentation
Dewan Shafiq
 
Bronquiectasias y hemoptisis.
Bronquiectasias y hemoptisis.Bronquiectasias y hemoptisis.
Bronquiectasias y hemoptisis.
Victor Cordova
 
Chronic Obstruction Pulmonary Disease
Chronic Obstruction Pulmonary DiseaseChronic Obstruction Pulmonary Disease
Chronic Obstruction Pulmonary Disease
Ahmed Azhad
 
Triple v dual therapy in copd
Triple v dual therapy in copdTriple v dual therapy in copd
Triple v dual therapy in copd
Jefferson Pike Jr.
 
Aspirin exacerbated respiratory disease (AERD)
Aspirin exacerbated respiratory disease (AERD)Aspirin exacerbated respiratory disease (AERD)
Aspirin exacerbated respiratory disease (AERD)
Chulalongkorn Allergy and Clinical Immunology Research Group
 
Catch up vaccine
Catch up vaccineCatch up vaccine
Catch up vaccinestudent
 
Management of acute severe asthma
Management of acute severe asthmaManagement of acute severe asthma
Management of acute severe asthma
charithwg
 
Update in CAP 2019
Update in CAP 2019Update in CAP 2019
Update in CAP 2019
Waheed Shouman
 
Management of severe asthma an update 2014
Management of severe asthma an update 2014Management of severe asthma an update 2014
Management of severe asthma an update 2014avicena1
 
Acute asthma what is new?
Acute asthma  what is new?Acute asthma  what is new?
Acute asthma what is new?
Dr.Venugopalan Poovathum Parambil
 
Bronchial Asthma: Definition,Pathophysiology and Management
Bronchial Asthma: Definition,Pathophysiology and ManagementBronchial Asthma: Definition,Pathophysiology and Management
Bronchial Asthma: Definition,Pathophysiology and Management
Marko Makram
 

What's hot (20)

Allergic bronchopulmonary aspergillosis
Allergic bronchopulmonary aspergillosisAllergic bronchopulmonary aspergillosis
Allergic bronchopulmonary aspergillosis
 
201911 - Rossi - L'asma grave è sempre “grave”?
201911 - Rossi - L'asma grave è sempre “grave”?201911 - Rossi - L'asma grave è sempre “grave”?
201911 - Rossi - L'asma grave è sempre “grave”?
 
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
An update on the management of Idiopathic Pulmonary Fibrosis (IPF)
 
difficult to treat asthma.pptx
difficult to treat asthma.pptxdifficult to treat asthma.pptx
difficult to treat asthma.pptx
 
Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma
Controlled Trial of Budesonide–Formoterol  as Needed for Mild AsthmaControlled Trial of Budesonide–Formoterol  as Needed for Mild Asthma
Controlled Trial of Budesonide–Formoterol as Needed for Mild Asthma
 
COPD new drugs new devices
COPD new drugs new devicesCOPD new drugs new devices
COPD new drugs new devices
 
Asthma Evolving approaches to treatment decisions
Asthma  Evolving approaches to treatment decisionsAsthma  Evolving approaches to treatment decisions
Asthma Evolving approaches to treatment decisions
 
Severe asthma management
Severe asthma managementSevere asthma management
Severe asthma management
 
GINA 2019 presentation
GINA 2019 presentationGINA 2019 presentation
GINA 2019 presentation
 
Bronquiectasias y hemoptisis.
Bronquiectasias y hemoptisis.Bronquiectasias y hemoptisis.
Bronquiectasias y hemoptisis.
 
Chronic Obstruction Pulmonary Disease
Chronic Obstruction Pulmonary DiseaseChronic Obstruction Pulmonary Disease
Chronic Obstruction Pulmonary Disease
 
Triple v dual therapy in copd
Triple v dual therapy in copdTriple v dual therapy in copd
Triple v dual therapy in copd
 
Aspirin exacerbated respiratory disease (AERD)
Aspirin exacerbated respiratory disease (AERD)Aspirin exacerbated respiratory disease (AERD)
Aspirin exacerbated respiratory disease (AERD)
 
Catch up vaccine
Catch up vaccineCatch up vaccine
Catch up vaccine
 
Management of acute severe asthma
Management of acute severe asthmaManagement of acute severe asthma
Management of acute severe asthma
 
Update in CAP 2019
Update in CAP 2019Update in CAP 2019
Update in CAP 2019
 
GINA-2023
GINA-2023GINA-2023
GINA-2023
 
Management of severe asthma an update 2014
Management of severe asthma an update 2014Management of severe asthma an update 2014
Management of severe asthma an update 2014
 
Acute asthma what is new?
Acute asthma  what is new?Acute asthma  what is new?
Acute asthma what is new?
 
Bronchial Asthma: Definition,Pathophysiology and Management
Bronchial Asthma: Definition,Pathophysiology and ManagementBronchial Asthma: Definition,Pathophysiology and Management
Bronchial Asthma: Definition,Pathophysiology and Management
 

Similar to The novel START trial.pptx

Asthma - GINA 2019
Asthma - GINA 2019Asthma - GINA 2019
Asthma - GINA 2019
Ahikam Devadason
 
GINA-2022-Whats-New-Slides.pptx
GINA-2022-Whats-New-Slides.pptxGINA-2022-Whats-New-Slides.pptx
GINA-2022-Whats-New-Slides.pptx
AkhilChitturi1
 
GINA-2022-Whats-New-Slides (1).pptx
GINA-2022-Whats-New-Slides (1).pptxGINA-2022-Whats-New-Slides (1).pptx
GINA-2022-Whats-New-Slides (1).pptx
TOMANDJERRY23
 
GINA-2022-Whats-New-Slides.pptx
GINA-2022-Whats-New-Slides.pptxGINA-2022-Whats-New-Slides.pptx
GINA-2022-Whats-New-Slides.pptx
NivethithaBharathi1
 
GINA-2022-Whats-New-Slides presentation.pptx
GINA-2022-Whats-New-Slides presentation.pptxGINA-2022-Whats-New-Slides presentation.pptx
GINA-2022-Whats-New-Slides presentation.pptx
shasshankk12345
 
Asthma management and GINA.pptx
Asthma management and GINA.pptxAsthma management and GINA.pptx
Asthma management and GINA.pptx
PawanVarshney3
 
GINA-2022-Whats-New-Slides.pptx
GINA-2022-Whats-New-Slides.pptxGINA-2022-Whats-New-Slides.pptx
GINA-2022-Whats-New-Slides.pptx
Edison Maldonado
 
ASTHMA.ppt
ASTHMA.pptASTHMA.ppt
ASTHMA.ppt
hufane1
 
Asthma Mangement: Time for a New Approach
Asthma Mangement: Time for a New ApproachAsthma Mangement: Time for a New Approach
Asthma Mangement: Time for a New Approach
Ashraf ElAdawy
 
MANAGEMENT OF ASTHMA IN CHILDREN.pptx
MANAGEMENT OF ASTHMA IN CHILDREN.pptxMANAGEMENT OF ASTHMA IN CHILDREN.pptx
MANAGEMENT OF ASTHMA IN CHILDREN.pptx
SangeethaVijian
 
ASMA-TEORIA Y DEFINICIONES BASICAS Y TRATAMIENTO
ASMA-TEORIA Y DEFINICIONES BASICAS Y TRATAMIENTOASMA-TEORIA Y DEFINICIONES BASICAS Y TRATAMIENTO
ASMA-TEORIA Y DEFINICIONES BASICAS Y TRATAMIENTO
VictorTullume1
 
Whats-new-in-GINA-2019.pptx
Whats-new-in-GINA-2019.pptxWhats-new-in-GINA-2019.pptx
Whats-new-in-GINA-2019.pptx
DrSampurnaSatapathy
 
asthma .pptx
asthma  .pptxasthma  .pptx
asthma .pptx
AfiqAsyraf27
 
Smart.pptx
Smart.pptxSmart.pptx
Ptt 2
Ptt 2Ptt 2
Asthma management in clinical practice
Asthma management in clinical practiceAsthma management in clinical practice
Asthma management in clinical practice
Dr.Mahmoud Abbas
 
GINA 2021 baru.pdf
GINA 2021 baru.pdfGINA 2021 baru.pdf
GINA 2021 baru.pdf
HendarsyahSuryadinat
 
Asthma phenotypes
Asthma phenotypesAsthma phenotypes
Asthma
AsthmaAsthma
Bronchial Asthma Management in Children GINA Updates
Bronchial Asthma Management in Children GINA UpdatesBronchial Asthma Management in Children GINA Updates
Bronchial Asthma Management in Children GINA Updates
ShubhamPandit60
 

Similar to The novel START trial.pptx (20)

Asthma - GINA 2019
Asthma - GINA 2019Asthma - GINA 2019
Asthma - GINA 2019
 
GINA-2022-Whats-New-Slides.pptx
GINA-2022-Whats-New-Slides.pptxGINA-2022-Whats-New-Slides.pptx
GINA-2022-Whats-New-Slides.pptx
 
GINA-2022-Whats-New-Slides (1).pptx
GINA-2022-Whats-New-Slides (1).pptxGINA-2022-Whats-New-Slides (1).pptx
GINA-2022-Whats-New-Slides (1).pptx
 
GINA-2022-Whats-New-Slides.pptx
GINA-2022-Whats-New-Slides.pptxGINA-2022-Whats-New-Slides.pptx
GINA-2022-Whats-New-Slides.pptx
 
GINA-2022-Whats-New-Slides presentation.pptx
GINA-2022-Whats-New-Slides presentation.pptxGINA-2022-Whats-New-Slides presentation.pptx
GINA-2022-Whats-New-Slides presentation.pptx
 
Asthma management and GINA.pptx
Asthma management and GINA.pptxAsthma management and GINA.pptx
Asthma management and GINA.pptx
 
GINA-2022-Whats-New-Slides.pptx
GINA-2022-Whats-New-Slides.pptxGINA-2022-Whats-New-Slides.pptx
GINA-2022-Whats-New-Slides.pptx
 
ASTHMA.ppt
ASTHMA.pptASTHMA.ppt
ASTHMA.ppt
 
Asthma Mangement: Time for a New Approach
Asthma Mangement: Time for a New ApproachAsthma Mangement: Time for a New Approach
Asthma Mangement: Time for a New Approach
 
MANAGEMENT OF ASTHMA IN CHILDREN.pptx
MANAGEMENT OF ASTHMA IN CHILDREN.pptxMANAGEMENT OF ASTHMA IN CHILDREN.pptx
MANAGEMENT OF ASTHMA IN CHILDREN.pptx
 
ASMA-TEORIA Y DEFINICIONES BASICAS Y TRATAMIENTO
ASMA-TEORIA Y DEFINICIONES BASICAS Y TRATAMIENTOASMA-TEORIA Y DEFINICIONES BASICAS Y TRATAMIENTO
ASMA-TEORIA Y DEFINICIONES BASICAS Y TRATAMIENTO
 
Whats-new-in-GINA-2019.pptx
Whats-new-in-GINA-2019.pptxWhats-new-in-GINA-2019.pptx
Whats-new-in-GINA-2019.pptx
 
asthma .pptx
asthma  .pptxasthma  .pptx
asthma .pptx
 
Smart.pptx
Smart.pptxSmart.pptx
Smart.pptx
 
Ptt 2
Ptt 2Ptt 2
Ptt 2
 
Asthma management in clinical practice
Asthma management in clinical practiceAsthma management in clinical practice
Asthma management in clinical practice
 
GINA 2021 baru.pdf
GINA 2021 baru.pdfGINA 2021 baru.pdf
GINA 2021 baru.pdf
 
Asthma phenotypes
Asthma phenotypesAsthma phenotypes
Asthma phenotypes
 
Asthma
AsthmaAsthma
Asthma
 
Bronchial Asthma Management in Children GINA Updates
Bronchial Asthma Management in Children GINA UpdatesBronchial Asthma Management in Children GINA Updates
Bronchial Asthma Management in Children GINA Updates
 

More from AbdirizakJacda

Mechanical Complications of Acute Myocardial Infraction-1.pptx
Mechanical Complications of Acute Myocardial Infraction-1.pptxMechanical Complications of Acute Myocardial Infraction-1.pptx
Mechanical Complications of Acute Myocardial Infraction-1.pptx
AbdirizakJacda
 
1- Introduction . RADIOLOGY-1.ppt
1- Introduction .         RADIOLOGY-1.ppt1- Introduction .         RADIOLOGY-1.ppt
1- Introduction . RADIOLOGY-1.ppt
AbdirizakJacda
 
2. Management gfgggfdffgggof HFrEF.pptx
2. Management  gfgggfdffgggof HFrEF.pptx2. Management  gfgggfdffgggof HFrEF.pptx
2. Management gfgggfdffgggof HFrEF.pptx
AbdirizakJacda
 
1.introductionjkctdshjncghvc surgery.pptx
1.introductionjkctdshjncghvc surgery.pptx1.introductionjkctdshjncghvc surgery.pptx
1.introductionjkctdshjncghvc surgery.pptx
AbdirizakJacda
 
HAP-VAP Seminar.pptx
HAP-VAP Seminar.pptxHAP-VAP Seminar.pptx
HAP-VAP Seminar.pptx
AbdirizakJacda
 
hypertensive emergency dr.bouni.pptx
hypertensive emergency dr.bouni.pptxhypertensive emergency dr.bouni.pptx
hypertensive emergency dr.bouni.pptx
AbdirizakJacda
 
ESIM Mock Exam.pptx
ESIM Mock Exam.pptxESIM Mock Exam.pptx
ESIM Mock Exam.pptx
AbdirizakJacda
 
12. Approach To Malabsorption.pptx
12. Approach To Malabsorption.pptx12. Approach To Malabsorption.pptx
12. Approach To Malabsorption.pptx
AbdirizakJacda
 
Acid-base disorders Abel T..pptx
Acid-base disorders Abel T..pptxAcid-base disorders Abel T..pptx
Acid-base disorders Abel T..pptx
AbdirizakJacda
 
dilated cardiomyopathy.pptx
dilated cardiomyopathy.pptxdilated cardiomyopathy.pptx
dilated cardiomyopathy.pptx
AbdirizakJacda
 
pericardialdiseases-190101163855 (1).pdf
pericardialdiseases-190101163855 (1).pdfpericardialdiseases-190101163855 (1).pdf
pericardialdiseases-190101163855 (1).pdf
AbdirizakJacda
 
Hypertensive Crises.pptx
Hypertensive Crises.pptxHypertensive Crises.pptx
Hypertensive Crises.pptx
AbdirizakJacda
 
26. Liver Abscess.pptx
26. Liver Abscess.pptx26. Liver Abscess.pptx
26. Liver Abscess.pptx
AbdirizakJacda
 
PC Slides_Steg_The REALITY trial.ppt
PC Slides_Steg_The REALITY trial.pptPC Slides_Steg_The REALITY trial.ppt
PC Slides_Steg_The REALITY trial.ppt
AbdirizakJacda
 
Case presentation.pptx
Case presentation.pptxCase presentation.pptx
Case presentation.pptx
AbdirizakJacda
 
final-draft_healthy_eating_weight_management_revised.pptx
final-draft_healthy_eating_weight_management_revised.pptxfinal-draft_healthy_eating_weight_management_revised.pptx
final-draft_healthy_eating_weight_management_revised.pptx
AbdirizakJacda
 
PARADISE-MI.pptx2be.pptx
PARADISE-MI.pptx2be.pptxPARADISE-MI.pptx2be.pptx
PARADISE-MI.pptx2be.pptx
AbdirizakJacda
 
PARADISE-MI.pptx
PARADISE-MI.pptxPARADISE-MI.pptx
PARADISE-MI.pptx
AbdirizakJacda
 
SGLT 2i, GLP1 Agonist and Insulin in T1DM.pptx
SGLT 2i, GLP1 Agonist and Insulin in T1DM.pptxSGLT 2i, GLP1 Agonist and Insulin in T1DM.pptx
SGLT 2i, GLP1 Agonist and Insulin in T1DM.pptx
AbdirizakJacda
 
CAPE COD trial.pptx
CAPE COD trial.pptxCAPE COD trial.pptx
CAPE COD trial.pptx
AbdirizakJacda
 

More from AbdirizakJacda (20)

Mechanical Complications of Acute Myocardial Infraction-1.pptx
Mechanical Complications of Acute Myocardial Infraction-1.pptxMechanical Complications of Acute Myocardial Infraction-1.pptx
Mechanical Complications of Acute Myocardial Infraction-1.pptx
 
1- Introduction . RADIOLOGY-1.ppt
1- Introduction .         RADIOLOGY-1.ppt1- Introduction .         RADIOLOGY-1.ppt
1- Introduction . RADIOLOGY-1.ppt
 
2. Management gfgggfdffgggof HFrEF.pptx
2. Management  gfgggfdffgggof HFrEF.pptx2. Management  gfgggfdffgggof HFrEF.pptx
2. Management gfgggfdffgggof HFrEF.pptx
 
1.introductionjkctdshjncghvc surgery.pptx
1.introductionjkctdshjncghvc surgery.pptx1.introductionjkctdshjncghvc surgery.pptx
1.introductionjkctdshjncghvc surgery.pptx
 
HAP-VAP Seminar.pptx
HAP-VAP Seminar.pptxHAP-VAP Seminar.pptx
HAP-VAP Seminar.pptx
 
hypertensive emergency dr.bouni.pptx
hypertensive emergency dr.bouni.pptxhypertensive emergency dr.bouni.pptx
hypertensive emergency dr.bouni.pptx
 
ESIM Mock Exam.pptx
ESIM Mock Exam.pptxESIM Mock Exam.pptx
ESIM Mock Exam.pptx
 
12. Approach To Malabsorption.pptx
12. Approach To Malabsorption.pptx12. Approach To Malabsorption.pptx
12. Approach To Malabsorption.pptx
 
Acid-base disorders Abel T..pptx
Acid-base disorders Abel T..pptxAcid-base disorders Abel T..pptx
Acid-base disorders Abel T..pptx
 
dilated cardiomyopathy.pptx
dilated cardiomyopathy.pptxdilated cardiomyopathy.pptx
dilated cardiomyopathy.pptx
 
pericardialdiseases-190101163855 (1).pdf
pericardialdiseases-190101163855 (1).pdfpericardialdiseases-190101163855 (1).pdf
pericardialdiseases-190101163855 (1).pdf
 
Hypertensive Crises.pptx
Hypertensive Crises.pptxHypertensive Crises.pptx
Hypertensive Crises.pptx
 
26. Liver Abscess.pptx
26. Liver Abscess.pptx26. Liver Abscess.pptx
26. Liver Abscess.pptx
 
PC Slides_Steg_The REALITY trial.ppt
PC Slides_Steg_The REALITY trial.pptPC Slides_Steg_The REALITY trial.ppt
PC Slides_Steg_The REALITY trial.ppt
 
Case presentation.pptx
Case presentation.pptxCase presentation.pptx
Case presentation.pptx
 
final-draft_healthy_eating_weight_management_revised.pptx
final-draft_healthy_eating_weight_management_revised.pptxfinal-draft_healthy_eating_weight_management_revised.pptx
final-draft_healthy_eating_weight_management_revised.pptx
 
PARADISE-MI.pptx2be.pptx
PARADISE-MI.pptx2be.pptxPARADISE-MI.pptx2be.pptx
PARADISE-MI.pptx2be.pptx
 
PARADISE-MI.pptx
PARADISE-MI.pptxPARADISE-MI.pptx
PARADISE-MI.pptx
 
SGLT 2i, GLP1 Agonist and Insulin in T1DM.pptx
SGLT 2i, GLP1 Agonist and Insulin in T1DM.pptxSGLT 2i, GLP1 Agonist and Insulin in T1DM.pptx
SGLT 2i, GLP1 Agonist and Insulin in T1DM.pptx
 
CAPE COD trial.pptx
CAPE COD trial.pptxCAPE COD trial.pptx
CAPE COD trial.pptx
 

Recently uploaded

How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
FFragrant
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
NEHA GUPTA
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Dr. Rabia Inam Gandapore
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
aljamhori teaching hospital
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
greendigital
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
bkling
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
SumeraAhmad5
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
GL Anaacs
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
MedicoseAcademics
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
Dr. Rabia Inam Gandapore
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
LanceCatedral
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
addon Scans
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
sisternakatoto
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
Dr. Rabia Inam Gandapore
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
Anujkumaranit
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Savita Shen $i11
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
MedicoseAcademics
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
د.محمود نجيب
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Saeid Safari
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
Savita Shen $i11
 

Recently uploaded (20)

How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptxHow STIs Influence the Development of Pelvic Inflammatory Disease.pptx
How STIs Influence the Development of Pelvic Inflammatory Disease.pptx
 
New Drug Discovery and Development .....
New Drug Discovery and Development .....New Drug Discovery and Development .....
New Drug Discovery and Development .....
 
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptxPharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
Pharynx and Clinical Correlations BY Dr.Rabia Inam Gandapore.pptx
 
basicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdfbasicmodesofventilation2022-220313203758.pdf
basicmodesofventilation2022-220313203758.pdf
 
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness JourneyTom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journey
 
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
 
heat stroke and heat exhaustion in children
heat stroke and heat exhaustion in childrenheat stroke and heat exhaustion in children
heat stroke and heat exhaustion in children
 
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...
 
Physiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of TastePhysiology of Special Chemical Sensation of Taste
Physiology of Special Chemical Sensation of Taste
 
Cervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptxCervical & Brachial Plexus By Dr. RIG.pptx
Cervical & Brachial Plexus By Dr. RIG.pptx
 
How to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for DoctorsHow to Give Better Lectures: Some Tips for Doctors
How to Give Better Lectures: Some Tips for Doctors
 
Flu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore KarnatakaFlu Vaccine Alert in Bangalore Karnataka
Flu Vaccine Alert in Bangalore Karnataka
 
263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,263778731218 Abortion Clinic /Pills In Harare ,
263778731218 Abortion Clinic /Pills In Harare ,
 
Superficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptxSuperficial & Deep Fascia of the NECK.pptx
Superficial & Deep Fascia of the NECK.pptx
 
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdfARTIFICIAL INTELLIGENCE IN  HEALTHCARE.pdf
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdf
 
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
Phone Us ❤85270-49040❤ #ℂall #gIRLS In Surat By Surat @ℂall @Girls Hotel With...
 
Physiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdfPhysiology of Chemical Sensation of smell.pdf
Physiology of Chemical Sensation of smell.pdf
 
KDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologistsKDIGO 2024 guidelines for diabetologists
KDIGO 2024 guidelines for diabetologists
 
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists  Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists
 
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #GirlsFor Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
For Better Surat #ℂall #Girl Service ❤85270-49040❤ Surat #ℂall #Girls
 

The novel START trial.pptx

  • 2. ASTHMA Journal of Allergy and Clinical Immunology. 2007;120(5):S94-S138.
  • 3. LEARNING OBJECTIVES Outline the major change in the 2019 Global Initiative for Asthma (GINA) guidelines Discuss budesonide-formoterol’s place in therapy for mild asthma based on recent literature Recognize the dose and dosage form that budesonide-formoterol is supplied as
  • 4. MEASUREMENTS OF ASTHMA CONTROL Severity Intrinsic intensity of the disease process Control Degree to which they are minimized Responsivene ss The ease with which control is achieved by therapy Journal of Allergy and Clinical Immunology. 2007;120(5):S94-S138.
  • 5. CONSEQUENCES OF UNCONTROLLED ASTHMA Airway remodeling Scarring of the lungs Permanent decline in respiratory function Journal of Allergy and Clinical Immunology. 2007;120(5):S94-S138.
  • 6. Beasley RD et al. NEJM. 2019; 380(21):2020-2030. NOVEL START TRIAL: CONTROLLED TRIAL OF BUDESONIDE- FORMOTEROL AS NEEDED FOR MILD ASTHMA
  • 7. PURPOSE ICS use is low as maintenance therapy for mild asthma An ICS + LABA takes advantage of a patient’s natural response to use therapy when symptomatic Two previous clinical trials have been done showing efficacy and safety in using budesonide-formoterol as needed These two trials had high internal validity, but low external validity Novel START trial was designed to overcome limitations of previous 2 trials Beasley RD et al. NEJM. 2019; 380(21):2020-2030.
  • 8. PREVIOUS TRIALS SYGMA-1 • Conclusion: inhaled budesonide-formoterol when used as needed was superior to terbutaline, but was inferior to budesonide maintenance therapy SYGMA-2 • Conclusion: inhaled budesonide-formoterol was non-inferior to the budesonide maintenance therapy for severe exacerbation • Bateman E et al. NEJM. 2018;378(20):1877-1887.
  • 9. CLINICAL QUESTION • In patients with mild asthma treated only with as-needed asthma, does budesonide+formoterol reliever therapy used as-needed reduce the risk of asthma exacerbations compared to albuterol as-needed?
  • 10. TRIAL DESIGN • Multicenter, open-label, parallel-group, randomized, controlled trial • N=668 • Albuterol (n=223) • Budesonide BID+albuterol PRN (n=225) • Budesonide+formoterol PRN (n=220) • Setting: 16 centers in New Zealand, United Kingdom, Italy, and Australia • Enrollment: 2016-2017 • Follow-up: 52 weeks • Analysis: Intention-to-treat • Primary outcome: Asthma exacerbations per patient per year
  • 11. POPULATION Inclusion Criteria • Aged 18-75 years • Asthma diagnosis, with one of the following: • If no severe exacerbations in the prior year, SABA use on ≥2 occasions in the prior 4 weeks and ≤2 occasions per day (average) in prior 4 weeks • If a severe exacerbation in the prior year (not requiring hospitalization), SABA use ≤2 occasions per day in the previous 4 weeks
  • 12. • Exclusion Criteria • Hospitalization for asthma in the previous 12 months, or any admissions to an ICU for asthma • Smoking with >20 PYH • Self-reported onset of respiratory symptoms after the ago of 40 years in current or previous smokers with at least a 10 pack-year smoking history • Maintenance therapy with ICS, LABA, leukotriene receptor antagonist, theophylline, anticholinergic agent or cromone in prior 3 months • Treatment with oral prednisone in the prior 6 weeks, or a home supply of prednisone for use in worsening asthma • COPD, bronchiectasis, ILD, HF, unstable CAD, AF, other significant cardiac disease • Pregnancy • Unwilling to switch asthma treatment • FEV1 ≤50% predicted at visit 1
  • 13.
  • 14. INTERVENTIONS • Randomized 1:1:1 to a group: • Albuterol PRN - Albuterol dose 100 ug • Budesonide BID+albuterol PRN - Budesonide dose 200 ug, albuterol dose 100 ug • Budesonide+formoterol PRN - Budesonide+formoterol dose 200-6 ug • Electronic monitors recorded inhaler use • Withdrawal from trial after a severe exacerbation (worsening asthma leading to prescription of systemic glucocorticoid treatment for at ≥3 days or hospitalization/ED visit leading to systemic glucocorticoid treatment), 3 exacerbations separated by ≥7 days, or unstable disease requiring change in medication from what they were assigned
  • 15. OUTCOMES • Presented as budesonide+formoterol PRN vs. albuterol PRN vs. budesonide BID+albuterol PRN Primary Outcomes • Annual rate of asthma exacerbationsExacerbations was defined as worsening asthma that leading to an urgent outpatient, ED, or inpatient medical care consultation, prescription of systemic glucocorticoids for any duration, or an episode of high β2-agonist use (>16 actuations of albuterol or >8 actuations of budesonide+formoterol in 24 hours).
  • 16.
  • 17. RESULTS: PRIMARY OUTCOME 0.4 0.175 0.195 0 0.05 0.1 0.15 0.2 0.25 0.3 0.35 0.4 0.45 Albuterol Group Budesonide Maintenance Group Budesonide-Formoterol Group Annualized Exacerbation Rate * Beasley RD et al. NEJM. 2019; 380(21):2020-2030. * P < 0.05
  • 18. Secondary outcomes • The risk of exacerbation in the budesonide–formoterol group was lower than that in the albuterol group, as assessed in a time-to- first-event analysis and did not differ significantly from that in the budesonide maintenance group. • Across all time points, the score on the ACQ-5 was lower in the budesonide–formoterol group than in the albuterol group, but was higher in the budesonide–formoterol group than in the budesonide maintenance group.
  • 19. STRENGHTS • Good trial design • Good monitoring and follow up. • Criticisms • Insufficiently powered (225 participants per study arm required to achieve sufficient power as per reported calculation) • Lack of smoking pack-year history (SPYH) stratification • Mean age of 35.6 limits external validity for older patient populations WEAKNESSES CRITICISM
  • 20. IMPLICATIONS • If available and not costly a very budesonide-formoterol will be practice changing in our setting
  • 21. MOVING FORWARD FDA approval for budesonide- formoterol Turbuhaler Changes in labeling of budesonide- formoterol Further trials with variety of doses and long-term effects Guideline update
  • 22. Low dose ICS whenever SABA taken, or daily LTRA, or add HDM SLIT Medium dose ICS, or add LTRA, or add HDM SLIT Add LAMA or LTRA or HDM SLIT, or switch to high dose ICS Add azithromycin (adults) or LTRA. As last resort consider adding low dose OCS but consider side-effects RELIEVER: As-needed short-acting beta2-agonist STEP 1 Take ICS whenever SABA taken STEP 2 Low dose maintenance ICS STEP 3 Low dose maintenance ICS-LABA STEP 4 Medium/high dose maintenance ICS-LABA STEP 5 Add-on LAMA Refer for assessment of phenotype. Consider high dose maintenance ICS-LABA, ± anti-IgE, anti-IL5/5R, anti-IL4R, anti-TSLP RELIEVER: As-needed low-dose ICS-formoterol STEPS 1 – 2 As-needed low dose ICS-formoterol STEP 3 Low dose maintenance ICS-formoterol STEP 4 Medium dose maintenance ICS-formoterol STEP 5 Add-on LAMA Refer for assessment of phenotype. Consider high dose maintenance ICS-formoterol, ± anti-IgE, anti-IL5/5R, anti-IL4R, anti-TSLP Treatment of modifiable risk factors and comorbidities Non-pharmacological strategies Asthma medications (adjust down/up/between tracks) Education & skills training Adults & adolescents 12+ years Personalized asthma management Assess, Adjust, Review for individual patient needs Symptoms Exacerbations Side-effects Lung function Patient satisfaction Confirmation of diagnosis if necessary Symptom control & modifiable risk factors (see Box 2-2B) Comorbidities Inhaler technique & adherence Patient preferences and goals CONTROLLER and PREFERRED RELIEVER (Track 1). Using ICS-formoterol as reliever reduces the risk of exacerbations compared with using a SABA reliever Other controller options for either track (limited indications, or less evidence for efficacy or safety) CONTROLLER and ALTERNATIVE RELIEVER (Track 2). Before considering a regimen with SABA reliever, check if the patient is likely to be adherent with daily controller See GINA severe asthma guide © Global Initiative for Asthma, www.ginasthma.org GINA 2022, Box 3-5A
  • 23. AUTHOR’S CONCLUSIONS • Among patients with mild asthma, the risk of asthma exacerbations was lower with budesonide-formoterol used as needed than with albuterol used as needed Beasley RD et al. NEJM. 2019; 380(21):2020- 2030.
  • 25. CURRENT BUDESONIDE- FORMOTEROL FORMULATION HFA inhaler available in the US Label: NOT for use during acute bronchospasm Asthma approved dose: 80 mcg/4.5 mcg or 160 mcg/4.5 mcg Formoterol onset of action: 15 minutes Albuterol onset of action: 25 minutes Budesonide- Formoterol. Lexi-Drugs. Lexicomp
  • 26. BUDESONIDE 80 MCG & FORMOTEROL 4.5 MCG BUDESONIDE 160 MCG & FORMOTEROL 4.5 MCG BUDESONIDE-FORMOTEROL Dose = 2 inhalations twice daily
  • 27. SUMMARY Budesonide-formoterol as-needed lowers exacerbation rates 2022 GINA guidelines have been updated to include using budesonide-formoterol as-needed first line for mild asthma Budesonide-formoterol is an HFA inhaler available as 2 strengths